Literature DB >> 30500162

Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies.

Salam Bashir1, Shani Leviatan Ben Arye1, Eliran Moshe Reuven1, Hai Yu2, Cristina Costa3, Manuel Galiñanes4, Tomaso Bottio5, Xi Chen2, Vered Padler-Karavani1.   

Abstract

Recognition of carbohydrates by antibodies can be affected by antigen composition and density. This had been investigated in a variety of controllable multivalent systems using synthetic carbohydrate antigens, yet such effects on anticarbohydrate antibodies in circulating human serum have not been fully addressed thus far. All humans develop a polyclonal and diverse response against carbohydrates containing a nonhuman sialic acid form, N-glycolylneuraminic acid (Neu5Gc). This red meat-derived monosaccharide is incorporated into a diverse collection of human glycans resulting in circulating anti-Neu5Gc antibodies in human sera. Such antibodies can cause exacerbation of diseases mediated by chronic inflammation such as cancer and atherosclerosis. We aimed to evaluate how different presentation modes of Neu5Gc-glycans can affect the detection of anti-Neu5Gc IgGs in human serum. Here, we compare serum IgG recognition of Neu5Gc-containing glycoproteins, glycopeptides, and synthetic glycans. First, Neu5Gc-positive or Neu5Gc-deficient mouse strains were used to generate glycopeptides from serum glycoproteins. Then we developed a reproducible ELISA to screen human sera against Neu5Gc-positive glycopeptides for detection of human serum anti-Neu5Gc IgGs. Finally, we evaluated ELISA screens against glycopeptides in comparison with glycoproteins, as well as against elaborated arrays displaying synthetic Neu5Gc-glycans. Our results demonstrate that the presentation mode and diversity of Neu5Gc-glycans are critical for detection of the full collection of human serum anti-Neu5Gc IgGs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30500162      PMCID: PMC6768799          DOI: 10.1021/acs.bioconjchem.8b00817

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  41 in total

Review 1.  The cluster glycoside effect.

Authors:  Joseph J Lundquist; Eric J Toone
Journal:  Chem Rev       Date:  2002-02       Impact factor: 60.622

2.  Does fibrinogen contain populations with different degree of sialylation?

Authors:  D Solís; T Díaz-Mauriño
Journal:  Thromb Res       Date:  1992-09-15       Impact factor: 3.944

Review 3.  The sialome--far more than the sum of its parts.

Authors:  Miriam Cohen; Ajit Varki
Journal:  OMICS       Date:  2010-08

4.  Multivalent carbohydrate recognition on a glycodendrimer-functionalized flow-through chip.

Authors:  Hilbert M Branderhorst; Rob Ruijtenbeek; Rob M J Liskamp; Roland J Pieters
Journal:  Chembiochem       Date:  2008-07-21       Impact factor: 3.164

5.  Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells.

Authors:  Dzung H Nguyen; Pam Tangvoranuntakul; Ajit Varki
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

Review 6.  The sweet and sour of cancer: glycans as novel therapeutic targets.

Authors:  Mark M Fuster; Jeffrey D Esko
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

7.  Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease.

Authors:  Vered Padler-Karavani; Hai Yu; Hongzhi Cao; Harshal Chokhawala; Felix Karp; Nissi Varki; Xi Chen; Ajit Varki
Journal:  Glycobiology       Date:  2008-07-31       Impact factor: 4.313

8.  High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems.

Authors:  Joseph C Manimala; Timothy A Roach; Zhitao Li; Jeffrey C Gildersleeve
Journal:  Glycobiology       Date:  2007-05-04       Impact factor: 4.313

9.  Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies.

Authors:  Oyindasola Oyelaran; Qian Li; David Farnsworth; Jeffrey C Gildersleeve
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

10.  N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution.

Authors:  Maria Hedlund; Pam Tangvoranuntakul; Hiromu Takematsu; Jeffrey M Long; Gary D Housley; Yasunori Kozutsumi; Akemi Suzuki; Anthony Wynshaw-Boris; Allen F Ryan; Richard L Gallo; Nissi Varki; Ajit Varki
Journal:  Mol Cell Biol       Date:  2007-04-09       Impact factor: 4.272

View more
  11 in total

1.  Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies.

Authors:  Shani Leviatan Ben-Arye; Christoph Schneider; Hai Yu; Salam Bashir; Xi Chen; Stephan von Gunten; Vered Padler-Karavani
Journal:  Bioconjug Chem       Date:  2019-04-24       Impact factor: 4.774

2.  Factors contributing to variability of glycan microarray binding profiles.

Authors:  J Sebastian Temme; Christopher T Campbell; Jeffrey C Gildersleeve
Journal:  Faraday Discuss       Date:  2019-10-30       Impact factor: 4.394

Review 3.  The Structural Complexity and Animal Tissue Distribution of N-Glycolylneuraminic Acid (Neu5Gc)-Terminated Glycans. Implications for Their Immunogenicity in Clinical Xenografting.

Authors:  Michael E Breimer; Jan Holgersson
Journal:  Front Mol Biosci       Date:  2019-07-19

Review 4.  Synthesis of N-Glycolylneuraminic Acid (Neu5Gc) and Its Glycosides.

Authors:  Anoopjit Singh Kooner; Hai Yu; Xi Chen
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

Review 5.  Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid.

Authors:  Sharon Yehuda; Vered Padler-Karavani
Journal:  Front Immunol       Date:  2020-01-23       Impact factor: 7.561

Review 6.  Targeting the "Sweet Side" of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis.

Authors:  Nora Bloise; Mohammad Okkeh; Elisa Restivo; Cristina Della Pina; Livia Visai
Journal:  Nanomaterials (Basel)       Date:  2021-01-22       Impact factor: 5.076

7.  Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.

Authors:  Tal Noy-Porat; Adva Mechaly; Yinon Levy; Efi Makdasi; Ron Alcalay; David Gur; Moshe Aftalion; Reut Falach; Shani Leviatan Ben-Arye; Shirley Lazar; Ayelet Zauberman; Eyal Epstein; Theodor Chitlaru; Shay Weiss; Hagit Achdout; Jonathan D Edgeworth; Raghavendra Kikkeri; Hai Yu; Xi Chen; Shmuel Yitzhaki; Shmuel C Shapira; Vered Padler-Karavani; Ohad Mazor; Ronit Rosenfeld
Journal:  iScience       Date:  2021-04-26

Review 8.  Sialic acid metabolism as a potential therapeutic target of atherosclerosis.

Authors:  Chao Zhang; Jingyuan Chen; Yuhao Liu; Danyan Xu
Journal:  Lipids Health Dis       Date:  2019-09-14       Impact factor: 3.876

Review 9.  From "Serum Sickness" to "Xenosialitis": Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc.

Authors:  Chirag Dhar; Aniruddha Sasmal; Ajit Varki
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

10.  Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Santé study.

Authors:  Salam Bashir; Leopold K Fezeu; Shani Leviatan Ben-Arye; Sharon Yehuda; Eliran Moshe Reuven; Fabien Szabo de Edelenyi; Imen Fellah-Hebia; Thierry Le Tourneau; Berthe Marie Imbert-Marcille; Emmanuel B Drouet; Mathilde Touvier; Jean-Christian Roussel; Hai Yu; Xi Chen; Serge Hercberg; Emanuele Cozzi; Jean-Paul Soulillou; Pilar Galan; Vered Padler-Karavani
Journal:  BMC Med       Date:  2020-09-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.